Frank Zaldivar
Papers
2
Total Citations
15
H-Index
2
About
Frank Zaldivar is a translational researcher whose work bridges urologic oncology and biomarker discovery, with a focus on improving outcomes for prostate cancer patients. His research centers on identifying urinary biomarkers that can predict disease aggressiveness and post-surgical complications. In his seminal 2014 study, Zaldivar demonstrated that urinary nerve growth factor (NGF) serves as a promising oncologic biomarker for prostate cancer aggressiveness, a finding that has garnered 13 citations and opened new avenues for non-invasive risk stratification. Building on this work, he investigated monocyte chemotactic protein-1 (MCP-1) as a predictor of prolonged urinary incontinence after radical prostatectomy. In a 2016 study, Zaldivar and his team collected pre-operative urine samples from men undergoing robotic radical prostatectomy and used ELISA to measure MCP-1 levels, correlating them with pad usage at 7, 30, and 60 days post-surgery. This work highlights his commitment to translating molecular insights into practical tools that can personalize patient counseling and recovery planning. Zaldivar’s contributions underscore the potential of urinary biomarkers to transform prostate cancer management, from diagnosis to survivorship.
Research Focus
Key Achievements
Top Papers
- 1
- 2